科创板挂牌后,百奥赛图“A+H” 双引擎欲推动中国创新药走向全球

野马财经
Dec 12, 2025

百奥赛图从上市到长期战略的逻辑延展。在抗体新药研发中,失败往往不是发生在终点,而是在起点就已经被“写好”。无论研发团队投入多少资源,如果候选抗体分子与人体环境不匹配,或者临床前验证模型无法真实模拟疾病机制,那条昂贵的研发路线就像一张错误的地图——越努力,越偏离终点。百奥赛图(688796.SH)的出现,正是试图纠正这两张“地图”的偏差。12月10日,公司在科创板成功上市,继2022年港交所挂牌后...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10